Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Amortization of Deferred Charges: 2019-2020

Historic Amortization of Deferred Charges for UroGen Pharma (URGN) over the last 2 years, with Dec 2020 value amounting to $1.6 million.

  • UroGen Pharma's Amortization of Deferred Charges fell 38.79% to $232,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $1.3 million, marking a year-over-year increase of 4.19%. This contributed to the annual value of $1.6 million for FY2020, which is 58.37% up from last year.
  • According to the latest figures from FY2020, UroGen Pharma's Amortization of Deferred Charges is $1.6 million, which was up 58.37% from $1.0 million recorded in FY2019.
  • In the past 5 years, UroGen Pharma's Amortization of Deferred Charges registered a high of $1.6 million during FY2020, and its lowest value of $1.0 million during FY2019.
  • For the 2-year period, UroGen Pharma's Amortization of Deferred Charges averaged around $1.3 million, with its median value being $1.3 million (2019).
  • Data for UroGen Pharma's Amortization of Deferred Charges shows a peak YoY soared of 58.37% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows UroGen Pharma's Amortization of Deferred Charges stood at $1.0 million in 2019, then spiked by 58.37% to $1.6 million in 2020.